Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 5:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Hidradenitis Suppurativa (HS) Clear all

Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04242446

View directory record Official record

Conditions: Hidradenitis Suppurativa
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older

Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more

Source: ClinicalTrials.gov public record

Updated May 18, 2026 · Synced May 22, 2026, 5:48 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

NCT04772885

View directory record Official record

Conditions: Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
Interventions: KT-474/Placebo, KT-474; Drug
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more

Source: ClinicalTrials.gov public record

Updated Oct 23, 2022 · Synced May 22, 2026, 5:48 AM EDT

Terminated Phase 2 Interventional Results available

A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)

NCT05348681

View directory record Official record

Conditions: Hidradenitis Suppurativa
Interventions: RIST4721, Placebo; Drug
Lead sponsor: Aristea Therapeutics, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 7 more

Source: ClinicalTrials.gov public record

Updated Jun 12, 2023 · Synced May 22, 2026, 5:48 AM EDT

Completed Phase 4 Interventional Results available

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

NCT02808975

View directory record Official record

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Placebo, Adalimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 9
States / cities: Beverly Hills, California • Encino, California • Irvine, California + 6 more

Source: ClinicalTrials.gov public record

Updated May 13, 2020 · Synced May 22, 2026, 5:48 AM EDT

Completed Not applicable Interventional Results available

Hidradenitis Suppurativa (HS) Tunneling Wounds

NCT04648631

View directory record Official record

Conditions: Hidradenitis Suppurativa
Interventions: antibiofilm surfactant wound gel (ABWG); Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older

Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Source: ClinicalTrials.gov public record

Updated Apr 1, 2024 · Synced May 22, 2026, 5:48 AM EDT

Recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

NCT06799000

View directory record Official record

Conditions: Hidradenitis Suppurativa
Interventions: Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years

Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 36
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • North Little Rock, Arkansas + 32 more

Source: ClinicalTrials.gov public record

Updated Mar 11, 2026 · Synced May 22, 2026, 5:48 AM EDT

Active, not recruiting Not applicable Interventional

Aviclear for Hidradenitis Suppurativa (HS)

NCT06801795

View directory record Official record

Conditions: Hidradenitis Suppurativa
Interventions: AviClear; Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 60 Years

Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Source: ClinicalTrials.gov public record

Updated Apr 22, 2026 · Synced May 22, 2026, 5:48 AM EDT

Recruiting Early Phase 1 Interventional

Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%

NCT06645821

View directory record Official record

Conditions: Hidradenitis Suppurativa (HS)
Interventions: EVO101; Drug
Lead sponsor: Virginia Clinical Research, Inc.; Other
Eligibility: 18 Years and older

Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Norfolk, Virginia

Source: ClinicalTrials.gov public record

Updated Dec 10, 2024 · Synced May 22, 2026, 5:48 AM EDT

Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT05620823

View directory record Official record

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Povorcitinib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older

Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 37
States / cities: Phoenix, Arizona • Arkansas City, Arkansas • Fort Smith, Arkansas + 32 more

Source: ClinicalTrials.gov public record

Updated Feb 9, 2026 · Synced May 22, 2026, 5:48 AM EDT

Completed Not applicable Interventional

Mindfulness Training Hidradenitis Suppurativa (HS)

NCT05642039

View directory record Official record

Conditions: Hidradenitis Suppurativa, Quality of Life
Interventions: Mindfulness Course, HS Educational Course; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older

Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Source: ClinicalTrials.gov public record

Updated Sep 1, 2025 · Synced May 22, 2026, 5:48 AM EDT

Active, not recruiting Phase 3 Interventional Results available

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

NCT04179175

View directory record Official record

Conditions: Hidradenitis Suppurativa
Interventions: secukinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years

Enrollment: 703 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 29
States / cities: Rogers, Arkansas • San Diego, California • Whittier, California + 22 more

Source: ClinicalTrials.gov public record

Updated Mar 10, 2026 · Synced May 22, 2026, 5:48 AM EDT

Recruiting Phase 3 Interventional

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182

View directory record Official record

Conditions: Hidradenitis Suppurativa
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older

Enrollment: 1,328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 87
States / cities: Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 73 more

Source: ClinicalTrials.gov public record

Updated Mar 3, 2026 · Synced May 22, 2026, 5:48 AM EDT

Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06212999

View directory record Official record

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Povorcitinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older

Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 61
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 51 more

Source: ClinicalTrials.gov public record

Updated Mar 22, 2026 · Synced May 22, 2026, 5:48 AM EDT

Completed No phase listed Observational

Hidradenitis Suppurativa Mail Survey

NCT03572738

View directory record Official record

Conditions: Hidradenitis Suppurativa
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older

Enrollment: 67 participants
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Source: ClinicalTrials.gov public record

Updated Nov 25, 2025 · Synced May 22, 2026, 5:48 AM EDT

Recruiting Not applicable Interventional

Radiotherapy for Refractory Hidradenitis Suppurativa

NCT07414550

View directory record Official record

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Radiated axilla; Radiation
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older

Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Cherry Hill, New Jersey • Philadelphia, Pennsylvania

Source: ClinicalTrials.gov public record

Updated May 14, 2026 · Synced May 22, 2026, 5:48 AM EDT

Recruiting Phase 2 Interventional

The Safety and Efficacy of Roflumilast Foam in HS

NCT07263230

View directory record Official record

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Roflumilast 0.3% topical foam; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Feb 10, 2026 · Synced May 22, 2026, 5:48 AM EDT

Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04242498

View directory record Official record

Conditions: Hidradenitis Suppurativa
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older

Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 24
States / cities: Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 21 more

Source: ClinicalTrials.gov public record

Updated May 18, 2026 · Synced May 22, 2026, 5:48 AM EDT

Recruiting Phase 2 Interventional

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07213973

View directory record Official record

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Povorcitinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years to 17 Years

Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Farmington, Connecticut + 18 more

Source: ClinicalTrials.gov public record

Updated May 7, 2026 · Synced May 22, 2026, 5:48 AM EDT

Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06603077

View directory record Official record

Conditions: Hidradenitis Suppurativa
Interventions: AVTX-009 Regimen 1, AVTX-009 Regimen 2, Placebo; Drug
Lead sponsor: Avalo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 36
States / cities: Scottsdale, Arizona • Tucson, Arizona • Northridge, California + 31 more

Source: ClinicalTrials.gov public record

Updated Apr 20, 2026 · Synced May 22, 2026, 5:48 AM EDT

Withdrawn Phase 4 Interventional

Botulinum Toxin-A for Hidradenitis Suppurativa

NCT06237465

View directory record Official record

Conditions: Hidradenitis Suppurativa, Hidradenitis Suppurativa \(HS\), Hidradenitis Suppurativa, Acne Inversa
Interventions: Normal saline, Botulinum toxin type A; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Guilford, Connecticut

Source: ClinicalTrials.gov public record

Updated Dec 15, 2025 · Synced May 22, 2026, 5:48 AM EDT

Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT05620836

View directory record Official record

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Povorcitinib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older

Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 38
States / cities: Scottsdale, Arizona • Arkansas City, Arkansas • Fayetteville, Arkansas + 33 more

Source: ClinicalTrials.gov public record

Updated Jan 8, 2026 · Synced May 22, 2026, 5:48 AM EDT

Recruiting No phase listed Observational

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

NCT07123038

View directory record Official record

Conditions: Rheumatoid Arthritis (RA), Hidradenitis Suppurativa (HS)
Interventions: Long Term Safety Monitoring Procedures; Other
Lead sponsor: Sonoma Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 71 Years

Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2040
U.S. locations: 10
States / cities: San Francisco, California • Stanford, California • Aurora, Colorado + 5 more

Source: ClinicalTrials.gov public record

Updated Apr 15, 2026 · Synced May 22, 2026, 5:48 AM EDT

Recruiting Phase 2 Interventional

A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa

NCT07384975

View directory record Official record

Conditions: Hidradenitis Suppurativa (HS)
Interventions: NAV-240, Placebo to match NAV-240; Drug
Lead sponsor: Navigator Medicines, Inc.; Industry
Eligibility: 18 Years to 70 Years

Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Phoenix, Arizona • Maitland, Florida • Miami, Florida + 6 more

Source: ClinicalTrials.gov public record

Updated Feb 2, 2026 · Synced May 22, 2026, 5:48 AM EDT

Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT03628924

View directory record Official record

Conditions: Hidradenitis Suppurativa
Interventions: Guselkumab dose 1, Guselkumab dose 2, Guselkumab dose 3, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older

Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 20
States / cities: Birmingham, Alabama • Largo, Florida • Ocala, Florida + 14 more

Source: ClinicalTrials.gov public record

Updated Feb 3, 2025 · Synced May 22, 2026, 5:48 AM EDT